The awaited moment has arrived: Elon Musk is starting human trials for Neuralink

Elon Musk, the trailblazing co-founder of Neuralink, has publicly announced the much-anticipated commencement of human trials slated for this year. This forward leap arrives on the heels of approval from the US government and stands as a testament to the revolutionary potential of Neuralink's technology, particularly for individuals with paraplegic or tetraplegic conditions.

In the face of ongoing inquiries concerning its animal trials, Neuralink has successfully navigated its path to a crucial clearance from the US Food and Drug Administration (FDA). This green light allows for the company's maiden human clinical trial and underscores a significant advancement in the sphere of brain-computer interfaces. The ultimate aim of these trials is not only to assess the safety and effectiveness of the company's technology in human subjects but also to bring hope to those grappling with paralysis-related conditions.

Musk, donning his various hats as the CEO of Tesla, Twitter, and SpaceX, chose the VivaTech event in Paris as his stage to unveil Neuralink's audacious plan of implanting neural chips into a human subject within the year. This declaration underscores Neuralink's unyielding commitment to revolutionize the realm of brain-computer interfaces.

The awaited moment has arrived: Elon Musk is starting human trials for Neuralink

In true Musk style, he shared the news with the event attendees, revealing that the world would have the opportunity to witness the groundbreaking procedure through a webcast. This implantation is deemed a monumental stride for Neuralink in its pursuit of augmenting human capacities through brain-chip technology. Given Musk's diverse leadership roles in various cutting-edge enterprises, this announcement has sparked significant curiosity regarding the potential ramifications of Neuralink's progress in neural implants.

However, Musk maintained an air of mystery by withholding specific details about the upcoming human trial, including the number of participants and the trial's duration.

Earlier in May, Neuralink crossed a significant threshold when the FDA sanctioned its first human clinical trial. This crucial approval not only sets the stage for Neuralink to scrutinize the safety and efficiency of its innovative technology in humans but also ignites immense potential for the future of brain-computer interfaces. The trial has sparked considerable excitement among researchers, medical practitioners, and the wider public.

Titanic tourist submarine goes missing! What was the problem?News & Culture